Abstract-Influences of r-butyrolactone (GBL) on GABA agonists-induced gastric acid secretion were studied in anesthetized rats. GBL potentiated the effect of GABA and GABA agonists on gastric acid secretion, and r-hydroxybutyric acid, a metabolite of GBL, tended to enhance the effect of GABA. However, GBL did not influence 2-deoxy-D glucose or bethanechol-stimulated acid secretion. A benzodiazepine, diazepam, also increased the secretagogue action of baclofen. A GABA antagonist, bicuculline, but not picrotoxin, inhibited the acid secretion stimulated by the combination of GBL and GABA or muscimol. Aminooxyacetic acid, an inhibitor of GABA transaminase, potentiated the effect of GABA. Dopamine receptor agonists and antagonist did not modify the effect of GABA. Neither GABA mimetic action of GBL nor its influences on the dopaminergic system are involved in the effect of the compound on gastric acid secretion. Although the possibility that GBL inhibits GABA degradation is not excluded, the compound appears to increase the sensitivity of GABA receptor to GABA mimetics in the gastric acid secretion.
Recently, GABA neuron has been found to be very important in the central nervous system control of gastric acid secretion (1) (2) (3) . For example, an intracerebroventricular GABA agonist (muscimol) was shown to produce a dose-dependent increase in gastric acid secretion (3) . A lipophilic derivative of GABA, 8-(p-chlorophenyl)-GABA (baclofen), also increased gastric acid secretion (2, 3) . On the other hand, dopamine agonists were found to inhibit gastric acid secretion cen trally stimulated by 2-deoxy-D-glucose or thyrotropin-releasing hormone (4, 5) . r Butyrolactone (GBL) is well known to interrupt an impulse flow on the dopaminergic neurons (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . A GBL's metabolite, y hydroxybutyric acid (G H BA), is structurally similar to GABA as shown in Fig. 1 .
Since these pharmacological evidences suggest that GBL modifies the central nervous system control of gastric acid secretion, we examined the influence of GBL on GABA agonists-induced gastric acid secretion in the rat.
Materials and Methods
Male Wistar rats (ST. substrain from Sankyo Lab. Co., Ltd.), weighing 180-220 g, were anesthetized with urethane (1.25 g/kg i.p.) after a 24 hr fast, but were allowed free access to water. A gastric acid secretion assay was performed as described by Watanabe and Goto (16) with a slight modification (5) . The total amount of the secreted acid was expressed in terms of aeq HCI/2 hr per animal. Basal secretion was low and almost constant during the experimental periods. Therefore, the data indicate value of acid output after drug treatment subtracted by the respective basal secretion. Intra cerebroventricular drug administration was carried out by the technique of Noble et al.
(17). Bicuculline dissolved in 0.1 N HCI was adjusted to pH 6.5 with 0.1 N NaOH. Diazepam, bromocriptine and haloperidol were suspended in a 1 % gum arabicum solution. Other compounds were dissolved in a saline solution. All drugs except intra cerebroventricular GABA (10 ,ul/rat) were administered in a volume of 1 ml/kg. Doses of apomorphine, bethanechol, bromocriptine, haloperidol and methamphetamine are ex pressed as the amount of salt. 
Results
GABA (400 and 800 mg/kg i.v.) produced a slight and short (less than 30 min) increase in the acid secretion. Pretreatment with GBL (200 mg/kg i.v.) 15 min before GABA extremely potentiated the acid secretion produced by 400 mg/kg of GABA during 2 hr (Table 1) . GBL alone did not stimulate basal acid secretion at 200 mg/kg i.v., but a higher dosage of the compound (400 mg/kg) Table 1 . Influence of r-butyrolactone (GBL) on GABA-induced gastric acid secretion
The values are means±S.E.M. of five experiments (the acid output after drug administration minus basal values). Basal secretion is 12.2±2.7 ueq HCI/30 min (n=20).
r-Butyrolactone (GBL), r-hydroxy butyric acid (GHBA) or muscimol (MUS) was given i.v. 15 min before the injection of GABA. **P<0.01 vs. GABA (400 mg/kg) or GBL (200 mg/kg). stimulated it. r-Hydroxybutyric acid, a GBL metabolite, tended to increase the response with 400 mg/kg of GABA, although it was not significant. GABA alone did not affect the acid secretion. Pyrrolidone (400 and 800 mg/kg i.v.), having chemical structure related to GBL, did not influence the acid secretion (data not shown). Muscimol, con trary to GBL, did not influence the action of GABA at the dose which slightly stimulated the basal secretion.
The action of muscimol and another GABA agonist, baclofen, was also potentiated by GBL as shown in Table 2 . Muscimol (0.2 mg/ kg i.v.) and baclofen (2.5 mg/kg s.c.) slightly increased the acid secretion, but the combination of either of these compounds with GBL remarkably potentiated the acid secretion. Table 3 shows the influence of GBL on the other secretagogues-induced acid secretion. Bethanechol (0.1 and 0.5 mg/kg s.c.) or 2 deoxy-D-glucose (100 and 200 mg/kg i.v.) induced a gastric acid secretion in a dose related manner. GBL did not influence the response with these secretagogues. Table 4 significantly the effect of the intravenous as well as intracerebroventricular GABA (Table  5) .
Dopamine agonists and an antagonist (haloperidol) did not influence the effect of GABA and the baclofen-stimulated acid secretion as shown in Table 6 . Figure 2 shows the inhibition of bicuculline (BCC), a GABA receptor antagonist, on the combined effect of GBL and GABA or MSC. BCC (1 or 2 mg/kg i.v.) inhibited the gastric acid secretion induced by the combination of Basal secretion is 11.3+2.8 peq HCI/30 min (n=16). Apomorphine, methamphetamine or haloperidol was given 15 min before the injection of GABA. Fig. 2 . Effects of GABA antagonists on the acid secretion stimulated by the combination of GBL and GABA or MSC. Each column shows the mean±S.E.M. of 6-10 rats. Abscissa: increased acid output during 2 hr after the injection of GABA or MSC. GBL was given 15 min before GABA, and GABA antagonists were given 15 min after GABA. **P<0.01 vs. GBL+GABA or GBL+MSC.
GBL and GABA or MSC, but picrotoxin (5 mg/kg i.v.) did not significantly influence the combined effect.
Discussion
GABA agonists (muscimol and baclofen) have been found to remarkably stimulate acid secretion via the central nervous system (1-3). High doses of GABA (400 and 800 mg/kg i.v.) produced only a slight increase in the acid secretion, presumably because the compound does not readily penetrate the blood-brain barrier (18) . High dose of GBL itself stimulated the gastric acid secretion as shown in Table 1 , and the gastric secre tagogue action of GBL was previously reported (2) . It is likely that the action of GBL in gastric acid secretion is due to its me tabolite (GHBA) because the structure is similar to GABA. However, GHBA did not induce the acid secretion. Since GBL, 200 mg/kg i.v., remarkably enhanced the effects of GABA as well as other GABA agonists, while muscimol or GHBA did not significantly potentiate the effects, it is not reasonable to ascribe its potentiating activity to its GABA agonistic action.
In the present study, potentiation of GABA action with GBL was inhibited by bicuculline, but not picrotoxin. While bicucul line is able to compete with GABA at putative receptor binding sites, picrotoxin cannot (19) . That is, the site of action of picrotoxin is different from the GABA affinity site in the post-synaptic receptor (20) . Therefore, GBL may increase the sensitivity of the affinity site for GABA. It is well known that a benzodiazepine, diazepam, enhances selectively the GABA mediated pre and post-synaptic inhibition in the cuneate nucleus (21) and the pre synaptic inhibition in the spinal cord (22) (23) (24) . Recently, further evidence that diazepam increased significantly the specific binding of muscimol to rat brain membranes was obtained (25) . Although it has not been reported that benzodiazepine enhanced the acid secretion by the GABA-ergic stimu lation, a high dose of diazepam potentiated baclofen (GABA agonist)-induced acid secretion in the present study. Therefore, it appears that GBL enhances the affinity of GABA receptors for GABA mimetics.
The administration of anesthetic doses of G H BA or its precursor, GBL, increases dopamine levels in the neostriatum (6-13).
GHBA has been shown to inhibit an impulse flow in the dopaminergic neurons (14, 15). Therefore, dopaminergic system modulation may be involved in the action of GBL on the gastric acid secretion in the present study. However, the above mentioned effect of GBL on the dopamine neurons has been obtained by a higher dose than that of the present study, and its action was mainly due to the metabolite, GHBA. GHBA did not signifi cantly potentiate the action of GABA (Table  1) . Furthermore, dopamine agonists and an antagonist did not influence the action of GABA or baclofen in the present study.
Since repeated administration of an in hibitor of GABA transaminase enhanced the effect of GABA in the gastric acid secretion, these results do not exclude the possibility that GBL inhibits GABA degradation.
Neither GABA mimetic action of GBL nor its influences on the dopaminergic system are involved in the effect of the compound on gastric acid secretion.
Although the pos sibility that GBL inhibits GABA degradation is not excluded, the compound appears to increase the sensitivity of GABA receptor to GABA mimetics in the gastric acid secretion.
